Is triamcinolone acetonide useful and safe in meralgia paresthetica? Randomized control trial

Study of efficacy and safety of Triamcinolone acetonide in patients with Meralgia Paresthetica: a Randomized Control Trial - ESTAMP

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/10/010000

Enrollment

100

Registered

2017-10-04

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Meralgia Paresthetica Health Condition 2: G571- Meralgia paresthetica

Interventions

Intervention1: Triamcinolone acetonide 40 mg single injection: Locally injected corticosteroid Control Intervention1: Normal Saline 1 mL

single injection: normal saline

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients in age group 18-80 years with spontaneous meralgia paresthetica (not related to surgical procedures in the region of the anterior superior iliac spine such as osteotomy for bone grafting, spinal surgeries etc). 2.Meralgia paresthetica is a clinical diagnosis: Patients have unpleasant paresthesias tingling or burning over the lateral aspect of the upper half to upper 2/3 of the thigh. It may be bilateral in 20% of cases.

Exclusion criteria

Exclusion criteria: • Subjects not giving consent • Meralgia paresthetica following surgical procedures on the iliac crest or the spine • Patients who have previously undergone surgical procedures to relieve pain such as transposition, separation from muscular entrapment etc. • Pregnant females • Females in reproductive age group, who are not using adequate contraception.

Design outcomes

Primary

Measure	Time frame
To study change in severity pain on a VAS scale from 0-10 in patients with meralgia paresthetica before and after injection of 40 mg of triamcinolone acetonide as compared to placebo injections.Timepoint: 2 weeks, 4 weeks	—

Secondary

Measure	Time frame
1.Onset of pain relief (days) 2.percentage of patients who had complete relief 3.Duration of pain relief (days/weeks) 4.proportion of patients who are responders (atleast 50% reduction in VAS Score) and 5.reduction in dosage of drugs used in pain relief of meralgia paresthetica in patients who undergo 40 mg triamcinolone acetonide injection in comparison with placebo 6.Adverse effects of triamcinolone injectionsTimepoint: 2 weeks, 4 weeks	—

Measure

Time frame

1.Onset of pain relief (days) 2.percentage of patients who had complete relief 3.Duration of pain relief (days/weeks) 4.proportion of patients who are responders (atleast 50% reduction in VAS Score) and 5.reduction in dosage of drugs used in pain relief of meralgia paresthetica in patients who undergo 40 mg triamcinolone acetonide injection in comparison with placebo 6.Adverse effects of triamcinolone injectionsTimepoint: 2 weeks, 4 weeks

—

Countries

India

Contacts

Public ContactVinay Goyal

All India Institute of Medical Sciences

drvinaygoyal@gmail.com9810470250

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026